The research project “Development of Radiometalated GRPR-Antagonists for Tumor Diagnosis and Therapy” coded Ε11902 with a 3-year duration (2014-2016) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Nuclear Medicine & Radiology Department, Erasmus, MC, Rotterdam, The Netherlands and Advanced Accelerator Applications. The latter partner is also sponsoring these activities aiming at the development of new theranostic radiopharmaceuticals based on GRPR-antagonists for cancer-targeting in human.
A major achievement of the research project “Development of Radiometalated GRPR-Antagonists for Tumor Diagnosis and Therapy” is the conclusion of preclinical evaluation of the theranostic radioligand [68Ga]Ga/[177Lu]Lu-NeoBOMB1 for targeting of GRPR-positive solid tumors in human. Advanced Accelerator Applications (a Novartis Company) has initiated an international multi-Center clinical study for the final development of the theranostic radiopharmaceutical product.
Previous Page